SynDevRx syndevrx.com


Public list: Pharma Startups (6570) Cancer Therapeutics (1180)

SynDevRx has developed a technology that increases the activity and safety of small molecule drugs using a conjugation technique. The company's technology increases a drug's therapeutic index by concentrating activity at the disease site. It provides small molecules with predictable and reliable physical properties that can speed up development time and lower costs while improving the PK profile. SynDevRx's lead drug candidate SDX-7320 targets the oncology market, and inhibits MetAP2 - an enzyme...Show all

SynDevRx has developed a technology that increases the activity and safety of small molecule drugs using a conjugation technique. The company's technology increases a drug's therapeutic index by concentrating activity at the disease site. It provides...Show all

Company (Alive / Active)

Phone: 617-401-3110

Fax:

One Broadway
14th Floor
Cambridge, 02142
Massachusetts, United States

Latest News

See more competitors data Competitors
Total Funding Date of Last Funding
SynDevRx $26M Jan 17, 2020
See all 14 competitors

Web Traffic

Rank

Show (-10)

Engagement (PVPU)

Show (+1%)

Domain Authority Score
Show
Page Views Per Million (PVPM)
Show
Reach Per Million
Show

SEO Statistics

Domain Authority Score Show
Page Authority Score Show
No. External Links Show
No. Links Show

Web Traffic Statistics - Growth

Per Week Per Month Per 6 Months Per Year
Rank Login to see details
Page Views Per Million Login to see details
Page Views Per User Login to see details
Reach Per Million Login to see details

Related SynDevRx Jobs

jobs by Indeed job
						search

Investors

Investor Investor Type Location Participating Rounds
See all 3 investors
There is no Board of Directors data available for this company. Please select another tab.

Competitors

Company Status Description Investors

BioDelivery Sciences International

Raleigh, North Carolina, United States
IPO / Went publicBioDelivery Sciences (BDSI) is a specialty pharmaceutical company<br/><br/><br/><br/>that is leveraging its novel and proprietary patented drug delivery technologies to develop and commercialize, either on its own or in partnerships with third parties, new applications of proven therapeutics.<br/><br/><br/><br/>The development strategy focuses on utilization of the FDA's 505(b)(2) approval process to potentially obtain timely and efficient app...Show allLogin to see details

The Medicines Company

Parsippany, New Jersey, United States
AcquiredThe Medicines Company's purpose is to save lives, alleviate suffering and contribute to the economics of healthcare by focusing on 3,000 leading acute/intensive care hospitals worldwide. The company's vision is to be a leading provider of solutions in three areas: acute cardiovascular care, surgery and perioperative care, and serious infectious disease care.Login to see details
See all 14 competitors

Patents

Title Application Date Patent Date Status
(Patent / Application)
Polymer-conjugated metap2 inhibitors, and therapeutic methods of use thereof Nov 16, 2018 Jul 28, 2020 Patent
Treatment for tumors driven by metabolic dysfunction Jan 11, 2017 May 12, 2020 Patent
Metap2 inhibitors and methods of treating obesity May 30, 2018 Mar 17, 2020 Patent
Fumagillol derivatives and polymorphs thereof Apr 06, 2018 May 14, 2019 Patent
Polymer-conjugated metap2 inhibitors, and therapeutic methods of use thereof Jul 26, 2017 Dec 25, 2018 Patent
See all 18 patents